PTPN11 and hepatocellular carcinoma: The survival benefit of sorafenib for patients with HCC is unsatisfactory due to the development of adaptive resistance, and SHP2 was observably upregulated in sorafenib-resistant HCC cell lines as well as patient-derived xenografts (Leung et al., 2019).